GlassScriptPhysician profile
Andrew P Schroeder
NPI 1740710482
$1,645.05
in general payments reported to CMS, 2019-2025
25 companies · $34.46 in 2025
The $34.46 reported for 2025 was less than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
See the full distribution for Sports Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $951 · 2020: $272 · 2021: $12.08 · 2022: $124 · 2023: $142 · 2024: $110 · 2025: $34.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $286.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $288.23 | 2019 | |
| Pfizer INC. | $247.91 | 2019-2020 | |
| Allergan, INC. | $206.24 | 2019-2020 | |
| Djo, LLC | $140.03 | 2022-2024 | Donjoy, Cmf |
| Astellas Pharma US INC | $124.93 | 2019 | |
| Mylan Specialty L.P. | $121.16 | 2019 | |
| Novo Nordisk INC | $76.29 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $48.83 | 2019 | |
| Corium, LLC | $41.47 | 2022 | |
| Smith+Nephew, INC. | $39.20 | 2024 | Renasys Touch, Pico, Acticoat 4" X 4" |
| Bioventus LLC | $38.79 | 2023-2024 | Durolane, Durolane |
| Abbott Laboratories | $35.16 | 2022-2025 | Eterna |
| Depuy Synthes Sales INC. | $29.16 | 2022-2023 | Monovisc, Peak |
| Abbvie INC. | $24.21 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $23.81 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Crossroads Orthopedics, LLC | $23.64 | 2022 | |
| Amarin Pharma, INC. | $18.32 | 2020 | |
| Janssen Pharmaceuticals, INC | $16.92 | 2024 | Xarelto |
| Amgen INC. | $16.82 | 2020 | |
| Sanofi Pasteur INC. | $16.80 | 2022 | |
| Avanos Medical | $14.81 | 2025 | Coolief Cooled Radiofrequency |
| Paratek Pharmaceuticals, INC. | $14.63 | 2024 | Nuzyra |
| Neurocrine Biosciences, INC. | $14.11 | 2019 | |
| Hydrocision, INC. | $12.08 | 2021 | |
| Ironshore Pharmaceuticals INC. | $11.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Schroeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.